Prevalence of Coronary Blood Flow Reserve Abnormalities Among Patients With Nonobstructive Coronary Artery Disease and Chest Pain

1998 ◽  
Vol 73 (12) ◽  
pp. 1133-1140 ◽  
Author(s):  
David Hasdai ◽  
David R. Holmes ◽  
Stuart T. Higano ◽  
John C. Burnett ◽  
Amir Lerman
Keyword(s):  
Coronary Artery Disease ◽  
Blood Flow ◽  
Chest Pain ◽  
Coronary Artery ◽  
Coronary Blood Flow ◽  
Flow Reserve ◽  
Nonobstructive Coronary Artery Disease ◽  
Artery Disease ◽  
Coronary Blood Flow Reserve

Assessment of the Effect of Coronary Occlusion on Aortic Valve Dynamics Using a Global 3D FSI Model

2012 ◽  
Author(s):  
Soroush Nobari ◽  
Rosaire Mongrain ◽  
Richard Leask ◽  
Raymond Cartier
Keyword(s):  
Coronary Artery Disease ◽  
Blood Flow ◽  
Coronary Artery ◽  
Coronary Blood Flow ◽  
Aortic Root ◽  
Calcific Aortic Stenosis ◽  
Mortality And Morbidity ◽  
Valve Dynamics ◽  
Artery Disease ◽  
Aortic Stiffening

Coronary artery disease (CAD) is considered to be a major cause of mortality and morbidity in the developing world. It has recently been shown that aortic root pathologies such as aortic stiffening and calcific aortic stenosis can contribute to the initiation and progression of this disease by affecting coronary blood flow [1,2]. Such pathologies influence the distensibility of the aortic root and therefore the hemodynamics of the entire region. As a consequence the coronary blood flow and velocity profiles will be altered [3,4,5] which could accelerate the development of an existing coronary artery disease. However, it would be very interesting to see if an occluded coronary artery would have a mutual impact on valvular dynamics and aortic root pathologies. This bi-directionality could aggravate and contribute to the progression of both the coronary and aortic root pathology.

13N-ammonia PET/CT stress myocardial blood flow compared to fractional flow reserve in coronary artery disease

2020 ◽  
Vol 41 (2) ◽  
pp. 133-138 ◽  
Author(s):  
Jouke J. Boer ◽  
Johan J.J.S. Kappelhof ◽  
Friso M. van der Zant ◽  
Maurits Wondergem ◽  
Hans(J) B.R.M. de Swart ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Blood Flow ◽  
Coronary Artery ◽  
Myocardial Blood Flow ◽  
Fractional Flow Reserve ◽  
Fractional Flow ◽  
Flow Reserve ◽  
Stress Myocardial Blood Flow ◽  
Pet Ct ◽  
Artery Disease

Testosterone Increases Coronary Blood flow in Men with Coronary Artery Disease

1998 ◽  
Vol 94 (s38) ◽  
pp. 5P-5P
Author(s):  
CM Webb ◽  
JG McNeill ◽  
GMC Rosano ◽  
P Coluns
Keyword(s):  
Coronary Artery Disease ◽  
Blood Flow ◽  
Coronary Artery ◽  
Coronary Blood Flow ◽  
Artery Disease

scholarly journals Microvascular Assessment of Ranolazine in Non-Obstructive Atherosclerosis

2020 ◽  
Vol 13 (12) ◽  
Author(s):  
Jin-Sin Koh ◽  
Olivia Y. Hung ◽  
Parham Eshtehardi ◽  
Arnav Kumar ◽  
Rani Rabah ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Fractional Flow ◽  
Flow Reserve ◽  
Nonobstructive Coronary Artery Disease ◽  
Angina Frequency ◽  
Duke Activity Status Index ◽  
Artery Disease ◽  
Status Index ◽  
Frequency Score

Background: Microvascular dysfunction is known to play a key role in patients with angina and nonobstructive coronary artery disease. We investigated the impact of ranolazine among patients with angina and nonobstructive coronary artery disease. Methods: In this randomized, double-blinded, placebo-controlled pilot trial, 26 patients with angina once weekly or more, abnormal stress test, and nonobstructive coronary artery disease (<50% stenosis by angiography and fractional flow reserve >0.80) were randomized 1:1 to ranolazine or placebo for 12 weeks. Primary end point was ΔSeattle Angina Questionnaire (SAQ) angina frequency score. Baseline and 3 months follow-up SAQ, Duke Activity Status Index scores along with invasive fractional flow reserve, coronary flow reserve (CFR), hyperemic myocardial resistance, and cardiopulmonary exercise testing measurements were performed. Results: No significant differences in ΔSAQ angina frequency scores ( P =0.53) or Duke Activity Status Index ( P =0.76) were observed between ranolazine versus placebo, although patients on ranolazine had lesser improvement in SAQ physical limitation scores ( P =0.02) compared with placebo at 3 months. There were no significant differences in ΔCFR or Δhyperemic myocardial resistance between ranolazine and placebo groups. Patients treated with ranolazine, compared with placebo, had no significant improvement in maximum rate of oxygen consumption measured during incremental exercise (VO 2 max) and peak metabolic equivalents of task. Interestingly, in the ranolazine group, patients with baseline CFR<2.0 demonstrated greater gain in CFR compared with those with baseline CFR≥2.0 ( P =0.02). Conclusions: Ranolazine did not demonstrate improvement in SAQ angina frequency score, invasive microvascular function, or peak metabolic equivalent compared with placebo at 3 months. Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT02147067.

Sign in / Sign up

Export Citation Format

Share Document